IMR Press / FBE / Volume 4 / Issue 3 / DOI: 10.2741/E425

Frontiers in Bioscience-Elite (FBE) is published by IMR Press from Volume 13 Issue 2 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Review

Molecular biomarkers of lung carcinoma

Show Less
1 Department of Pathology and Cytology, University Hospital of Zagreb, Jordanovac 104, 10000 Zagreb, Croatia
2 University of Zagreb School of Medicine, Croatian Institute for Brain Research, Salata 12, 10000 Zagreb, Croatia

*Author to whom correspondence should be addressed.

Academic Editor: Nives Pecina-Slaus

Front. Biosci. (Elite Ed) 2012, 4(3), 865–875; https://doi.org/10.2741/E425
Published: 1 January 2012
(This article belongs to the Special Issue Biology of brain tumors)
Abstract

Lung carcinoma is still the leading cause of cancer deaths in men and women. There is a constantly increasing need to find molecular biomarkers for lung cancer which can be used for risk stratification, early detection, treatment selection, prognosis and monitoring for recurrence. Recent advances in imaging and improved bronchoscopic techniques have intensified interest in lung carcinoma screening techniques, especially in new molecular markers which can help cytopathologists to make a definitive diagnosis on very small specimens in non-invasive, non-expensive, simple and efficient manner. Several decades of intensive research have originated numerous potential lung carcinoma molecular biomarkers but only few turned out to be useful in clinic. The review describes types of biomarkers, sources and techniques for their identification in cancer diagnosis and therapy. A deep understanding of each biomarker will be a key to efficiently diagnose lung carcinomas and direct patients toward beneficial drugs based on individual patient profile.

Keywords
Lung
Carcinoma
Molecular Biomarkers
Review
Share
Back to top